Inventia Life Science
Inventia Life Science develops world-leading bioprinting technology for advanced medical research, enabling 3D cell culture and tissue engineering applications.
- CEO / Founder
- Dr. Julio Ribeiro
- Team Size
- 65
- Stage
- Growth Stage
- Total Funding
- $50.0M
- Latest Round
- Series B
- Key Investors
- Blackbird Ventures, In-Q-Tel, AirTree, HESTA
Technology & Products
Key Products
RASTRUM 3D Bioprinter, RASTRUM Allegro (2nd generation), LIGO Surgical Tool for in-situ tissue reconstruction, Bioink reagents and consumables
Technological Advantage
Proprietary drop-on-demand bioprinting technology that creates complex 3D tissue models faster and more consistently than manual methods
Differentiation
Value Proposition
Automates 3D cell culture with reproducible, scalable bioprinting technology that accelerates drug discovery and tissue engineering research.
How They Differentiate
Automation-first approach with high throughput capabilities versus competitors manual bioprinting systems
Market & Competition
Target Customers
Research institutions, pharmaceutical companies, biotechnology laboratories
Industry Verticals
Life Sciences, Pharmaceutical Research, Biotechnology, Tissue Engineering
Competitors
CELLINK/Cytiva, Organovo, Aspect Biosystems
Growth & Milestones
Growth Metrics
$15M ARR as of September 2025; 65 employees across 3 continents (Oceania, North America, Europe); 4 of top 10 global pharma companies as customers
Major Milestones
2013: Founded in Sydney; 2017: First institutional funding from Blackbird Ventures; 2019: Series A funding, RASTRUM platform development; 2021: AU$35M Series B led by Blackbird, US market entry; 2022: HESTA investment, MSD partnership announced; 2023: India market entry via Biotron Healthcare; 2025: RASTRUM Allegro launch, reached $15M ARR
Notable Customers
MSD/Merck (first pharma in Europe to use RASTRUM), Multiple top 10 global pharmaceutical companies, Leading research institutions worldwide, Biotron Healthcare (India distribution)